Press Release: Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo

Dow Jones11-06

Ginkgo provides an update on its third quarter financial results and the growth of its two prevailing offerings built on one autonomous lab platform: Autonomous Labs and Cloud Lab

BOSTON--(BUSINESS WIRE)--November 05, 2026-- 

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the third quarter of 2026 that ended September 30, 2026. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com.

Third Quarter 2026 Financial Results

   --  Third quarter 2026 Revenue of $28 million compared to $29 million in 
      the comparable prior year period, a decrease of 6%. Revenue increased 
      from $20 million in the second quarter of 2026. 
 
   --  Third quarter 2026 GAAP net loss from continuing operations of ($41) 
      million, compared to ($73) million in the comparable prior year period. 
 
 
   --  Third quarter 2026 Adjusted EBITDA of ($22) million, improved from 
      ($53) million in the comparable prior year period. 
 
   --  Cash, cash equivalents and marketable securities balance as of 
      September 30, 2026 of $285 million. 
 
   --  Third quarter 2026 cash burn of $27 million. 

"Ginkgo now has two core offerings built on one autonomous lab platform, " said Jason Kelly, Co-founder and CEO of Ginkgo Bioworks. "This quarter we announced the sale of an autonomous lab to a top-tier pharma company, Novo, alongside new government wins with ARPA-H and the NSF. Our Cloud Lab runs experiments on Nebula, the world's largest autonomous lab, giving pharma an onshore alternative to overseas CROs and giving frontier AI labs a new engine for training data. With the U.S. government now treating autonomous labs as national infrastructure, we believe Ginkgo is well positioned to lead the transition from the bench to autonomous research."

Recent Business Highlights & Strategic Positioning

   --  Two prevailing offerings built on one autonomous lab platform. 
 
          --  Autonomous Labs Equipment: we sell RAC + Catalyst systems to 
             pharma, national labs, universities and the U.S. government, 
             including Novo, Pacific Northwest National Laboratory, the NSF and 
             ARPA-H. 
 
          --  Cloud Lab Services: we run experiments in Nebula, the world's 
             largest autonomous lab with more than 100 reconfigurable 
             automation carts (RACs), delivering onshore ADME, DRUG-seq and 
             antibody data for pharma, and AI training data for frontier labs 
             and techbio companies. 
 
          --  The U.S. government is making autonomous labs national 
             infrastructure through the Genesis Mission, the NSF's $400 
             million Programmable Cloud Laboratories (PCL) Test Bed, and the 
             $1.5 billion X-Labs initiative, where Ginkgo is providing access 
             to Nebula, as announced by the White House Office of Science and 
             Technology Policy on October 8. 
 
 
 
   --  Autonomous Labs are growing with new deals. 
 
          --  Novo: an autonomous lab sale to a top-tier pharma company at 
             Novo's new Waltham, Massachusetts R&D site. 
 
          --  ARPA-H GIVE: subcontract worth up to $17.5 million to put RACs 
             and Catalyst into RNA-medicine manufacturing for the first time. 
 
 
          --  Building on momentum from previously-announced Caltech, 
             University of Maryland and Northwestern commissions of 
             Ginkgo-built labs under the NSF's PCL Test Bed, and MIT Media 
             Lab's construction of a RAC-based cloud lab. 
 
 
 
   --  Cloud Lab is growing with new pharma logos and AI data generation. 
 
          --  Our ADME-One service is orders of magnitude cheaper than WuXi, 
             with work done in Boston; 22 ADME customers signed in Q3 and 20 
             were first-time Ginkgo customers. 
 
          --  Takeda, Argenx, Lundbeck and AbbVie founded our Antibody 
             Developability Consortium; GSK, Novartis and Biogen also signed 
             new work. 
 
          --  Frontier AI labs like OpenAI are using our Cloud Lab for AI data 
             generation. 
 
 

Full Year 2026 Outlook

   --  Ginkgo reaffirms expected total cash burn of ($150)-($125) million in 
      2026. 

Conference Call Details

Ginkgo will host a videoconference today, Thursday, November 5, beginning at 4:30 p.m. ET. The presentation will include an overview of the third quarter 2026, recent business updates, a discussion on Ginkgo's outlook, as well as a moderated question and answer session.

To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.

A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.

Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/

Audio-Only Dial Ins:

+1 646 876 9923 (New York - ET)

+1 301 715 8592 (Washington DC - ET)

+1 305 224 1968 (Miami - ET)

+1 689 278 1000 (Orlando - ET)

+1 312 626 6799 (Chicago - CT)

+1 507 473 4847 (Minnesota - CT)

+1 346 248 7799 (Houston - CT)

+1 719 359 4580 (Colorado - MT)

+1 408 638 0968 (San Jose - PT)

Webinar ID: 952 0773 4867

If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our website at https://investors.ginkgobioworks.com/events/ for updated dial-in information.

About Ginkgo Bioworks

Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "Cloud Lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com, read our blog, or follow us on social media channels such as X (@Ginkgo), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.

Forward-Looking Statements of Ginkgo Bioworks

This press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, including with respect to technology adaptations to meet our customers' needs and the integration of our autonomous lab platform with third-party artificial intelligence models, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, potential customer success, including successful application of our offerings by our customers, expected benefits from our strategic partnerships and collaborations (including with named partners such as Novo and OpenAI), the anticipated growth, scaling, capacity, capabilities and competitive position of our autonomous lab (including Nebula) and of our Cloud Lab, Datapoints and Solutions offerings, our beliefs and estimates regarding the size, composition, growth and pace of adoption of the market for autonomous laboratory and related services (including the displacement of manual laboratory work), expectations concerning increased government investment in and contracting for autonomous laboratory infrastructure, expectations regarding the development, performance and future enhancements of our platform and new product and service introductions, and expectations with regard to revenue, including our ability to meet all milestones and achieve the maximum revenue available under certain of our customer arrangements, expenses, our full year 2026 outlook including the total cash burn guidance, and the market environment, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may, " "should," "will," "would," "will be," "will continue," "will likely result," "target," "goal," "aim," "design," "forecast," "outlook," "guidance," "seek" "position," and similar expressions, as well as the negatives of such terms. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards

and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our platform programs and assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith, (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies, including potential adverse effects from the U.S. government shutdown, (xiv) our ability to scale, expand the capacity of, and continue to develop the capabilities of our autonomous lab (including Nebula) on the timelines and to the extent we anticipate, (xv) the pace and degree to which autonomous laboratory infrastructure is adopted by, and displaces manual laboratory work in, the broader life sciences and industrial biotechnology markets, (xvi) the actual size, composition and growth of the addressable markets we target, which may differ materially from our estimates, (xvii) our ability to integrate our autonomous lab platform with third-party artificial intelligence models and other technologies, and the rate of development and adoption of such technologies, (xviii) our ability to maintain and expand strategic partnerships and customer relationships, including those with named partners referenced in this release, and (xix) the risks relating to significant disruptions to our and our service providers' information technology systems or data security incidents. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 26, 2026, Ginkgo's quarterly report on Form 10-Q, once filed, and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

Use of Non-GAAP Financial Measures

Certain of the financial measures included in this release, including Adjusted EBITDA, cash flow and cash burn, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo's financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, and should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation in the Appendix of this quarter's earnings presentation for additional information regarding certain of the non-GAAP financial measures included in this release, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo's most comparable GAAP financial measures. Ginkgo does not reconcile its forward-looking non-GAAP financial measures to the corresponding GAAP measures, due to variability and difficulty in making accurate forecasts and projections and/or certain information not being ascertainable or accessible; and because not all of the information, such as unrealized equity gains and losses necessary for a quantitative reconciliation of these forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measure, can be predicted with reasonable accuracy and is available to Ginkgo without unreasonable efforts. For the same reasons, Ginkgo is unable to address the probable significance of the unavailable information. Ginkgo provides non-GAAP financial measures that it believes will be achieved, however it cannot accurately predict all of the components of the adjusted calculations and the GAAP measures may be materially different than the non-GAAP measures.

Ginkgo Bioworks Holdings, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share data)

 
                      As of September 30, 2026     As of December 31, 2025 
                     ---------------------------  -------------------------- 
Assets 
Current assets: 
Cash and cash 
 equivalents          $               84,504       $              167,202 
Marketable 
 securities                          200,857                      255,418 
Accounts 
 receivable, net                      11,485                       24,026 
Accounts receivable 
 - related parties                        --                          229 
Prepaid expenses 
 and other current 
 assets (includes 
 $4,208 and zero 
 from related 
 parties)                             13,995                       24,963 
                         -------------------          ------------------- 
Total current 
 assets                              310,841                      471,838 
Restricted cash and 
 marketable 
 securities, 
 non-current                          84,237                       38,138 
Property, plant and 
 equipment, net                      152,347                      167,371 
Operating lease 
 right-of-use 
 assets                              341,494                      360,918 
Investments                            8,949                       15,066 
Equity method 
investments                            5,607                           -- 
Intangible assets, 
 net                                  39,731                       53,482 
Other non-current 
 assets                                1,246                        9,029 
Assets held for 
 sale                                     --                        3,854 
                         -------------------          ------------------- 
Total assets          $              944,452       $            1,119,696 
                         ===================          =================== 
Liabilities and 
Stockholders' 
Equity 
Current 
liabilities: 
Accounts payable      $                7,181       $               10,566 
Deferred revenue 
 (includes $98 and 
 $98 from related 
 parties)                              6,388                       18,946 
Accrued expenses 
 and other current 
 liabilities 
 (includes $5,564 
 and zero from 
 related parties)                     52,280                       66,458 
                         -------------------          ------------------- 
Total current 
 liabilities                          65,849                       95,970 
Non-current 
liabilities: 
Deferred revenue, 
 net of current 
 portion (includes 
 $64,810 and 
 $64,787 from 
 related parties)                     71,977                       75,182 
Operating lease 
 liabilities, 
 non-current                         397,198                      417,078 
Other non-current 
 liabilities                          16,791                       22,876 
                         -------------------          ------------------- 
Total liabilities                    551,815                      611,106 
                         -------------------          ------------------- 
Commitments and 
contingencies (Note 
10) 
Stockholders' 
equity: 
Preferred stock, 
$0.0001 par value; 
200,000,000 shares 
authorized; none 
issued                                    --                           -- 
Common stock, 
 $0.0001 par value 
 (Note 8)                                  6                            6 
Additional paid-in 
 capital                           6,713,117                    6,657,053 
Accumulated deficit               (6,320,601)                  (6,150,320) 
Accumulated other 
 comprehensive 
 income                                  115                        1,851 
                         -------------------          ------------------- 
Total stockholders' 
 equity                              392,637                      508,590 
                         -------------------          ------------------- 
Total liabilities 
 and stockholders' 
 equity               $              944,452       $            1,119,696 
                         ===================          =================== 
 

Ginkgo Bioworks Holdings, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited)

(in thousands, except share data)

 
                             Three Months Ended      Nine Months Ended September 
                               September 30,                     30, 
                         --------------------------  ---------------------------- 
                             2026          2025          2026          2025 
                          ----------    ----------    ----------    ---------- 
Revenue (1)              $    27,711   $    29,380   $    67,341   $   106,744 
 
Costs and operating 
expenses: 
Cost of other revenue          1,806         4,625         6,623        14,095 
Research and 
 development                  40,945        69,353       137,075       193,646 
General and 
 administrative               28,593        36,986        97,198       111,690 
Restructuring charges             --           721            --         8,753 
                          ----------    ----------    ----------    ---------- 
Total operating 
 expenses                     71,344       111,685       240,896       328,184 
                          ----------    ----------    ----------    ---------- 
Loss from operations         (43,633)      (82,305)     (173,555)     (221,440) 
Other income (expense): 
    Interest income, 
     net                       3,060         5,742         9,888        17,906 
    Loss on equity 
     method investment        (2,008)           --        (6,681)           -- 
    Gain (loss) on 
     investments                (287)        3,684           486          (238) 
    Other income 
     (expense), net            1,613          (474)       (4,725)       (6,280) 
                          ----------    ----------    ----------    ---------- 
Total other income 
 (expense)                     2,378         8,952        (1,032)       11,388 
                          ----------    ----------    ----------    ---------- 
Loss from continuing 
 operations before 
 income taxes                (41,255)      (73,353)     (174,587)     (210,052) 
Income tax (benefit) 
 expense                        (271)            1          (223)         (194) 
                          ----------    ----------    ----------    ---------- 
Net loss from 
 continuing operations   $   (40,984)  $   (73,354)  $  (174,364)  $  (209,858) 
Net income (loss) from 
 discontinued 
 operations, net of 
 tax                              --        (7,401)        4,083       (22,154) 
                          ----------    ----------    ----------    ---------- 
Net loss                 $   (40,984)  $   (80,755)  $  (170,281)  $  (232,012) 
                          ==========    ==========    ==========    ========== 
Net income (loss) per 
share: 
    From continuing 
     operations          $     (0.64)  $     (1.32)  $     (2.82)  $     (3.82) 
    From discontinued 
     operations                   --         (0.13)         0.07         (0.40) 
                          ----------    ----------    ----------    ---------- 
    Total net loss per 
     share               $     (0.64)  $     (1.45)  $     (2.75)  $     (4.22) 
                          ==========    ==========    ==========    ========== 
 
    Weighted average 
     common shares 
     outstanding:         63,966,054    55,633,718    61,890,748    54,916,539 
Comprehensive loss: 
    Net loss                 (40,984)      (80,755)     (170,281)     (232,012) 
Other comprehensive 
(loss) income: 
    Foreign currency 
     translation 
     adjustment                 (515)           27        (1,128)        3,462 
    Unrealized (loss) 
     gain on 
     available-for-sale 
     securities                 (320)          316          (608)          340 
                          ----------    ----------    ----------    ---------- 
Total other 
 comprehensive (loss) 
 income                         (835)          343        (1,736)        3,802 
                          ----------    ----------    ----------    ---------- 
Comprehensive loss       $   (41,819)  $   (80,412)  $  (172,017)  $  (228,210) 
                          ==========    ==========    ==========    ========== 
 

(1) Includes related party revenue of zero for the three months ended September 30, 2026 and 2025, and zero and $8,518 for the nine months ended September 30, 2026 and 2025, respectively.

Ginkgo Bioworks Holdings, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

 
                                       Nine Months Ended September 30, 
                                   --------------------------------------- 
                                           2026                2025 
                                       -------------       ------------ 
Cash flows from operating 
activities: 
Net loss                            $       (170,281)     $    (232,012) 
Net income (loss) from 
 discontinued operations, net of 
 tax                                           4,083            (22,154) 
                                       -------------       ------------ 
Net loss from continuing 
 operations                                 (174,364)          (209,858) 
Adjustments to reconcile net loss 
to net cash used in operating 
activities: 
Depreciation and amortization                 37,152             43,695 
Stock-based compensation                      31,117             51,226 
(Gain) loss on investments                      (486)               275 
Loss on equity method investment               6,681                 -- 
Change in fair value of notes 
 receivable                                    6,759              5,685 
Change in fair value of 
 contingent consideration                         --             (4,232) 
Non-cash lease expense                        19,423             22,449 
Accretion of discount on 
 marketable securities                            89             (2,502) 
Other non-cash activity                       (1,057)             1,611 
Changes in operating assets and 
liabilities: 
    Accounts receivable                        4,968              1,448 
    Prepaid expenses and other 
     current assets                            3,211               (775) 
    Operating lease right-of-use 
     assets                                       --              3,814 
    Other non-current assets                     297                (38) 
    Accounts payable, accrued 
     expenses and other current 
     liabilities                             (14,312)            17,432 
    Deferred revenue, current and 
     non-current zero and 
     $(7,958) from related 
     parties                                 (14,443)           (27,448) 
    Operating lease liabilities, 
     current and non-current                 (16,713)           (18,793) 
    Other non-current liabilities             (5,276)             4,459 
                                       -------------       ------------ 
Net cash used in operating 
 activities - continuing 
 operations                                 (116,954)          (111,552) 
Net cash used in operating 
 activities - discontinued 
 operations                                   (2,353)           (11,829) 
                                       -------------       ------------ 
Net cash used in operating 
 activities                                 (119,307)          (123,381) 
Cash flows from investing 
activities: 
Purchases of marketable debt 
 securities                                 (216,800)          (401,838) 
Maturities of marketable debt 
 securities                                  231,108             73,599 
Purchases of property and 
 equipment                                    (6,552)            (7,660) 
Proceeds from sale of investment               1,850                 -- 
Other                                            512                511 
                                       -------------       ------------ 
Net cash provided by (used in) 
 investing activities                         10,118           (335,388) 
                                       -------------       ------------ 
Cash flows from financing 
activities: 
Proceeds from ATM offering                    23,795             10,317 
Payment of issuance costs related 
 to ATM offering                                (802)              (355) 
Principal payments on finance 
 leases                                          (19)              (329) 
                                       -------------       ------------ 
Net cash provided by financing 
 activities                                   22,974              9,633 
                                       -------------       ------------ 
Effect of foreign exchange rates 
 on cash and cash equivalents                    (80)               353 
                                       -------------       ------------ 
Net decrease in cash, cash 
 equivalents and restricted cash             (86,295)          (448,783) 
 
Cash and cash equivalents, 
 beginning of period                         167,202            561,572 
Restricted cash, beginning of 
 period                                       45,169             44,171 
                                       -------------       ------------ 
Cash, cash equivalents and 
 restricted cash, beginning of 
 period                                      212,371            605,743 
 
Cash and cash equivalents, end of 
 period                                       84,504            111,065 
Restricted cash, end of period                41,572             45,895 
                                       -------------       ------------ 
Cash, cash equivalents and 
 restricted cash, end of period     $        126,076      $     156,960 
                                       =============       ============ 
 

The following table presents summary results of the Company's reportable segment, including significant expenses, and a reconciliation to loss from continuing operations before income taxes (in thousands):

 
                      Three Months Ended      Nine Months Ended 
                        September 30,           September 30, 
                     --------------------  ------------------------ 
                       2026       2025        2026        2025 
                      -------    -------    --------    -------- 
Cell Engineering 
Revenue              $ 27,711   $ 29,380   $  67,341   $ 106,744 
Costs and operating 
expenses: 
    Cost of other 
     revenue (1)        1,608      2,994       5,752       9,980 
    Research and 
     development 
     (1)               26,670     50,954      87,208     130,689 
    General and 
     administrative 
     (1)                9,317     13,758      33,148      49,397 
Stock-based 
 compensation (2)       7,767     15,249      32,512      51,732 
Depreciation and 
 amortization          12,038     13,624      37,152      43,695 
Restructuring 
 charges (3)               --        721          --       8,753 
Carrying cost of 
 excess space (net 
 of sublease 
 income) (4)           13,989     14,328      44,063      38,416 
Merger, acquisition 
 and divestiture 
 related expense 
 (income) (5)             (45)        57       1,061      (4,478) 
Other (income) 
 expense, net (6)      (2,378)    (8,952)      1,032     (11,388) 
                      -------    -------    --------    -------- 
Loss from 
 continuing 
 operations before 
 income taxes        $(41,255)  $(73,353)  $(174,587)  $(210,052) 
                      =======    =======    ========    ======== 
 

(1) The costs and operating expenses exclude expenses which are separately captioned below.

(2) Includes $0.1 million and $0.2 million in employer payroll taxes for three months ended September 30, 2026 and 2025, respectively, and $1.4 million and $0.7 million for nine months ended September 30, 2026 and 2025, respectively.

(3) See Note 3, Restructuring, for composition of costs.

(4) The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces.

(5) Represents transaction and integration costs directly related to mergers, acquisitions, and divestitures, including: (i) legal, consulting, and accounting fees associated with acquisitions; (ii) post-acquisition employee retention bonuses; (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions; and (iv) securities litigation costs.

(6) Includes interest income, interest expense, gain and loss on investments, changes in fair value of certain assets and liabilities, and other gains and losses.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261105540481/en/

 
    CONTACT:    INVESTORS: 

investors@ginkgobioworks.com

MEDIA:

press@ginkgobioworks.com

 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment